Otonomy Inc - ESG Rating & Company Profile powered by AI
The webpage of Otonomy Inc is assembled by All Street Sevva using cutting edge NLP. Complete Sustainability assessment of Otonomy Inc can be accessed by signing in. If you work at Otonomy Inc and you wish to use your Sustainability aseessment, please get in touch.
Otonomy Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 4.0, social score of 2.7 and governance score of 6.9.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1156 | Vectus Biosystems Ltd | 4.7 | High |
| 1156 | Zynerba Pharmaceuticals Inc | 4.7 | High |
| 1199 | Otonomy Inc | 4.6 | High |
| 1199 | Allergan Inc | 4.6 | High |
| 1199 | AroCell AB (publ) | 4.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Otonomy Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Otonomy Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Otonomy Inc report the average age of the workforce?
Sign up for free to unlockDoes Otonomy Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Otonomy Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Otonomy Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Otonomy Inc offer flexible work?
Sign up for free to unlockDoes Otonomy Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Otonomy Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Otonomy Inc conduct supply chain audits?
Sign up for free to unlockDoes Otonomy Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Otonomy Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Otonomy Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Otonomy Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Otonomy Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Otonomy Inc disclose water use targets?
Sign up for free to unlockDoes Otonomy Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Otonomy Inc have a product recall in the last two years?
Sign up for free to unlockDoes Otonomy Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Otonomy Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Otonomy Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Otonomy Inc disclose parental leave metrics?
Sign up for free to unlockDoes Otonomy Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Otonomy Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Otonomy Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Otonomy Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Otonomy Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Otonomy Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Otonomy Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Otonomy Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Otonomy Inc disclose its waste policy?
Sign up for free to unlockDoes Otonomy Inc report according to TCFD requirements?
Sign up for free to unlockDoes Otonomy Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Otonomy Inc disclose energy use targets?
Sign up for free to unlockDoes Otonomy Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Otonomy Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Otonomy Inc
These potential risks are based on the size, segment and geographies of the company.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.